The mRNA moment of 2020-2021 made the message famous, but the patents that matter most cover the envelope, and Translate Bio's 2021 grants make that explicit. US11185595B2 and its siblings US11052159B2 and US10888626B2 - all titled "Lipid nanoparticle compositions and methods for mRNA delivery" and issued in 2021 - claim the LNP composition itself.
Read the CPC tags and the claim center is obvious: A61K 9/1271 and A61K 9/1272 (liposome/nanoparticle formulations), A61K 48/0008 (genetic-material delivery). These are formulation classes. The encoded protein - the part the public hears about - is largely incidental to the claim; what is claimed is the lipid composition that gets any mRNA into cells.
Why does the vehicle carry the invention? Because naked mRNA is fragile and immunogenic; the enabling step was the ionizable-lipid nanoparticle that protects it and releases it inside the cell. The claim limitation that decides scope is the lipid composition - the specific components and ratios - not the sequence of the cargo.
The family pattern is itself informative. Multiple grants in one year with nearly identical titles and overlapping CPC profiles is the signature of a continuation strategy: the assignee files repeatedly off one specification to claim the composition from several angles, building redundancy against any single claim being narrowed. A reader should treat these as one family, not three independent inventions.
For freedom-to-operate, the consequence is that an mRNA therapeutic's biggest IP exposure is rarely its sequence - it is the delivery formulation. Programs cleared the cargo and then collided with the LNP estate, which is why the 2020-2021 lipid-nanoparticle grants from Translate Bio, Moderna, Alnylam, and Acuitas became the most heavily-licensed corner of the field.